Navigation Links
InfuSystem Holdings Provides Business Update and Comments on Fourth Quarter 2007 Financial Results
Date:3/18/2008

Improved Efficacy of Cancer Drugs and Cost Savings Driving Demand for

Continuous Infusion of Chemotherapy

NEW YORK, March 18 /PRNewswire-FirstCall/ -- InfuSystem Holdings, Inc. (OTC Bulletin Board: INHI; INHIW; INHIU), the leading provider of ambulatory infusion pump services for administering chemotherapy, today announced financial results for the fourth quarter of 2007. InfuSystem Holdings' results include results of operations for InfuSystem, Inc. from October 26, 2007 through December 31, 2007.

InfuSystem, Inc. supplies oncology practices, hospitals and their patients with ambulatory infusion pumps and related services. InfuSystem also provides 24/7 nursing support to address questions that patients may have about their pump treatment or other questions related to the pump. Continuous infusion pumps allow for the gradual delivery of a drug over a period of days in the privacy of one's home, compared to bolus infusion chemotherapy treatments that are given in a single high dose over a short period of time. Improved efficacy of the drugs, patient comfort, reimbursement to doctors for appropriate services and continuity of care all play a role in the growing trend toward this form of treatment. The company has approximately 60% penetration of oncologist practices in the United States, and agreements with managed care organizations covering over 125 million managed care lives.

Recent Highlights:

-- Completed the acquisition of InfuSystem, Inc.

-- Former president and co-founder of InfuSystem, Steve Watkins, appointed

chief executive officer

-- Sean M. Whelan, CPA, hired as chief financial officer

-- David M. Haar hired as vice president of marketing

-- Scott L. Chesky appointed vice president of strategic development

Mr. Sean McDevitt, chairman of the board, commented, "Following the acquisition of InfuSystem, we are now well underway to completing all of the immediate objectives we had established. Specifically, Steve Watkins, former president and co-founder of InfuSystem took over as chief executive officer of the combined companies. Janet Skonieczny will continue as vice president of operations, Tony Norkus will continue as vice president of sales, and the rest of the management team for InfuSystem will remain intact. Additionally, we hired a first-class chief financial officer and a new vice president of marketing with extensive industry experience. At the same time, we have begun to invest more heavily in national sales and marketing initiatives-the results of which have already become apparent heading into 2008. Most recently, we added a new vice president of strategic development and look forward to a very active year in terms of establishing joint ventures and strategic alliances, as well as identifying potential acquisition candidates with complementary products and services."

Mr. Steve Watkins, chief executive officer, commented, "Sales for the fourth quarter and full year 2007 were consistent with InfuSystem, Inc.'s results for the same periods in 2006. The lengthy acquisition process had the anticipated slowing effect on our sales organization. Following the acquisition, we immediately put in place our aggressive plans to resume and accelerate organic growth-including enhanced training, as well as new directives and incentive plans for the sales force. Overall, we see enormous opportunities ahead as a stand-alone public company and expect demand for continuous infusion pump therapy to continue its momentum of the past few years. Improved efficacy of the drugs as well as greater patient comfort compared to traditional bolus treatment are contributing to increased awareness of continuous infusion. The therapy is advantageous to payors, including managed care organizations, because it is generally less expensive than homecare or hospitalization and may help lower the costs incurred to treat the side-effects that often accompany traditional bolus."

Mr. Watkins continued, "Colorectal cancer (CRC) is the third most common cancer in both men and women. Protocols involving continuous infusion therapy are widely recognized as the standard of care for treatment of stage III CRC - and we are beginning to see treatment expanding to include stage II and stage IV as well. At the same time, continuous infusion protocols have also been approved for other forms of cancer, thereby greatly enhancing the addressable patient population for InfuSystem. Currently, over 120 drug therapy clinical trials involving continuous infusion therapy are being conducted and our plan is to expand our services to patients fighting other cancers. We expect to achieve this efficiently and cost-effectively as InfuSystem already has a strong foothold within the oncology community. We will start by educating our existing base of physicians and oncology nurses, which now includes over 1,500 practices across the United States. Given these strong relationships, we also look forward to leveraging our distribution channel by augmenting our offering to include safety products, disposables and other related items."

Mr. Watkins concluded, "As a leading nationwide provider of ambulatory infusion pump services, InfuSystem is ideally positioned for growth in this expanding yet highly fragmented market. Moreover, we believe we have a very scalable business model and are already benefiting from our status as a stand- alone public company, which has enabled us to begin aggressively pursuing these opportunities. At December 31, 2007, we had approximately $4 million of cash and we continue to generate very strong cash flow heading into 2008, which provides us tremendous flexibility to enhance our capital structure, strengthen our balance sheet and pursue strategic acquisitions going forward."

Financial Results

Revenue for the fourth quarter ended December 31, 2007 was $6.6 million, versus $0 for the same period in 2006, which reflects the revenues recognized by InfuSystem Holdings, Inc. following the acquisition of InfuSystem, Inc. from I-Flow Corporation on October 25, 2007. Revenue for the year ended December 31, 2007 was $6.6 million, versus $0 for the year ended December 31, 2006.

Operating income for the fourth quarter of 2007 was $1.0 million versus an operating loss of $1.9 million for the same period in 2006. The operating loss for the year ended December 31, 2007 was $1.5 million versus an operating loss of $20.8 million for 2006. The increase in operating income for the fourth quarter of 2007 and decrease in operating loss for the full year reflect revenue and operating expenses recorded for InfuSystem, Inc. following the acquisition, and lower stock-based compensation expense.

The net loss for the fourth quarter of 2007 was $1.9 million, or a loss of $0.11 per share, compared to net income of $0.2 million or $0.01 per share, for the same period in 2006. The net loss for the fourth quarter of 2007 included a $0.3 million charge for stock-based compensation, a $2.6 million charge for loss on derivative financial instruments, $0.8 million of expenses related to the transaction, and a $0.3 million gain from interest income.

The net loss for the year ended December 31, 2007 was $2.8 million, or a loss of $0.15 per share, versus a net loss of $7.9 million or $0.58 per share, for 2006. The net loss for 2007 included a $1.8 million charge for stock-based compensation, a $3.3 million charge for loss on derivative financial instruments, $1.8 million of expenses related to the transaction, and a $3.9 million gain from interest income.

InfuSystem Holdings, Inc. also announced that it intends to file a Form 12b-25 with the U.S. Securities and Exchange Commission to extend the filing date of its Form 10-K for the fiscal year ended December 31, 2007 by fifteen calendar days because the financial statements of its predecessor, InfuSystem, Inc., for the fiscal years ended December 31, 2006 and 2005 and for the period from January 1, 2007 through October 25, 2007, which are required to be included in the Form 10-K as predecessor financial statements, have not yet been completed and provided to InfuSystem Holdings, Inc. by the predecessor's former owner. InfuSystem Holdings, Inc. plans to file its Form 10-K as soon as possible, and in any event within the fifteen calendar days filing deadline.

Upon filing its Form 10-K, InfuSystem Holdings, Inc. will include additional financial information with regards to the complete fourth quarter of 2007 and the complete 2007 calendar year, including revenues of predecessor InfuSystem and successor InfuSystem for the respective time periods.

About InfuSystem Holdings, Inc.

InfuSystem is the leading provider of ambulatory infusion pump services for oncologists and their patients in the U.S. These pumps allow for the gradual delivery of a drug over a period of days in the privacy of one's home, compared to bolus infusion chemotherapy treatments that are given in a single high dose over a short period of time. Improved efficacy of the drugs, patient comfort, reimbursement to doctors for appropriate services and continuity of care all play a role in the growing trend toward this form of treatment. InfuSystem's pumps are primarily used for colorectal cancer, but they have been approved for other forms of cancer, thereby greatly enhancing the market opportunity for InfuSystem.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements. These risks and uncertainties include general economic conditions, as well as other risks detailed from time to time in InfuSystem's publicly filed documents.

(Tables follow)

InfuSystem Holdings, Inc.

CONSOLIDATED BALANCE SHEETS

December 31, December 31,

(in thousands, except share data) 2007 2006

ASSETS

Current Assets:

Cash and cash equivalents 3,960 427

Investments held in trust - 98,151

Accounts receivable, less allowance for

doubtful accounts of $1638 and $0 at

December 31,2007 and 2006, respectively;

December 31, 2007 includes $103 due

from I-Flow 6,304 -

Inventory supplies 364 -

Prepaid expenses and other current assets 1,263 446

Deferred income taxes 4 -

Deferred acquisition costs - 1,274

Total Current Assets 11,895 100,298

Property & equipment, Net 13,504 -

Deferred debt issuance costs, net 1,918 -

Goodwill 56,544 -

Intangible assets, net 32,565 -

Total Assets 116,426 100,298

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities:

Accounts payable 1,076 353

Other current liabilities 700 598

Income taxes payable 1,186 -

Deferred underwriting fees - 5,468

Derivative liabilities 12,407 9,113

Current portion of long-term debt payable

to I-Flow 2,044 -

Total Current Liabilities 17,413 15,532

Long-term debt payable to I-Flow, net

of current portion 30,250 -

Deferred income taxes 4 -

Total Liabilities 47,667 15,532

Commitments:

Common stock subject to possible conversion - 19,620

Stockholders' Equity

Preferred stock, $.0001 par value:

authorized 1,000,000 shares; none issued - -

Common stock, $.0001 par value; authorized

200,000,000 shares; issued 18,315,430 and

21,041,918, respectively; outstanding

16,824,295 and 18,625,252, respectively 2 2

Additional paid-in capital 79,437 73,028

Retained deficit (10,680) (7,884)

Total Stockholders' Equity 68,759 65,146

Total Liabilities and Stockholders' Equity 116,426 100,298

InfuSystem Holdings, Inc.

CONSOLIDATED STATEMENTS OF OPERATIONS

For The Twelve and Three Months Ended December 31, 2007 and 2006

3 Months 3 Months

Year Ended Year Ended Ended Ended

(in thousands, except December December December December

per share data) 31, 2007(1) 31, 2006 31, 2007(1) 31, 2006

Net revenues $6,582 $- $6,582 $-

Operating expenses (8,079) (20,824) (5,618) (1,928)

Operating (loss) income (1,497) (20,824) 964 (1,928)

Other (expense) income (189) 14,003 (2,475) 2,523

(Loss) income before income

taxes (1,686) (6,821) (1,511) 595

Income tax expense (1,110) (1,038) (357) (426)

Net (loss) income (2,796) (7,859) (1,868) 169

Net (loss) income per share:

basic (0.15) (0.58) (0.11) 0.01

diluted (0.15) (0.58) (0.11) 0.01

Weighted average shares

outstanding:

basic 18,299,600 13,661,117 17,333,261 18,625,252

diluted N/A N/A N/A 21,919,762

(1) InfuSystem Holdings' 2007 results do not include results of operations for InfuSystem, Inc. for the full fourth quarter or the full year; they only include results of operations for InfuSystem, Inc. from October 26, 2007 through December 31, 2007. Prior to October 26, 2007, the Company (known as HAPC, Inc. at the time) was in the development stage.


'/>"/>
SOURCE InfuSystem Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MBF Healthcare Acquisition Corp. and Critical Homecare Solutions Holdings, Inc. to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference
2. NightHawk Radiology Holdings, Inc. Announces Senior Executive Departures
3. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
4. MBF Healthcare Acquisition Corp. and Critical Homecare Solutions Holdings, Inc. to Present at the 2008 UBS Healthcare Services Conference
5. Zimmer Holdings to Present at Wachovia Healthcare Conference
6. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
7. H2Diesel Holdings Announces Test Burn Agreement With Mirant Corp.
8. China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results
9. Zimmer Holdings Announces Support for Elimination of Super-Majority Voting Requirements
10. Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
11. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® ... provides a free webinar on Performing Quality Investigations: Getting to Root ... CT at no charge. , Incomplete investigations are still a major concern to ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016  The American College of ... Trade Show Executive Magazine as one of the fastest-growing ... May 25-27 at the Bellagio in Las Vegas ... the highest percentage of growth in each of the following ... exhibiting companies and number of attendees. The 2015 ACMG Annual ...
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
Breaking Biology News(10 mins):